The excitement around Moderna’s cancer vaccine is cooling. Here’s why.
Investors had “incredibly high” expectations around the Phase 3 data for the drugmaker’s experimental cancer treatment.
Madrid, Spain saw Moderna CEO Stéphane Bancel in high spirits after a decade of hard work led to a breakthrough in cancer treatment. With the successful presentation of the first Phase 3 study, intismeran, an mRNA-based therapy developed in collaboration with Merck, was set to demonstrate its potential in enhancing outcomes for melanoma patients.
Bancel, speaking from the European Society for Medical Oncology annual meeting, expressed his excitement, recalling the initial skepticism surrounding intismeran. He emphasized the years of dedication and collaboration that had finally paid off, noting that many experts had doubted the viability of cancer vaccines. Bancel’s interview with STAT shed light on the future prospects of intismeran, and how this success could reshape the company’s research and development strategies. Readers interested in a comprehensive account should consult STAT+ for the full story.
Written by urgent.news from STAT News's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
